Tiny doses of atropine: unlocking the Eye's response to slow nearsightedness

NCT ID NCT07674966

Completed Knowledge-focused Sponsor: University of California, Berkeley Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study investigates how low doses of atropine eye drops (0.01%, 0.02%, and 0.05%) affect pupil size and the eye's ability to focus in healthy adults aged 18 to 40. Researchers aim to compare different dosing methods and recovery times, and to see if iris color influences the effects. The findings could help optimize atropine treatment for myopia (nearsightedness).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atropine eye drops (0.01%, 0.02%, 0.05%)
What this could lead to: If successful, this could help refine dosing strategies for using low-dose atropine to slow myopia progression in children.
What could go wrong: This is a small, early-phase study in healthy adults, not patients. Results may not translate to real-world myopia treatment or predict long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOPIA

Contacts and locations

Locations

University of California, Berkeley

Berkeley, California, 94720-2020, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.